The known unknowns of HPV natural history
PE Gravitt - The Journal of clinical investigation, 2011 - Am Soc Clin Investig
The discovery that certain high-risk strains of human papillomavirus (HR-HPV) cause nearly
100% of invasive cervical cancer has spurred a revolution in cervical cancer prevention by …
100% of invasive cervical cancer has spurred a revolution in cervical cancer prevention by …
Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally
JA Dykens, CE Peterson, HK Holt… - Frontiers in Public …, 2023 - frontiersin.org
Human papillomavirus (HPV) infection is responsible for many cancers in both women and
men. Cervical cancer, caused by HPV, is the fourth most common cancer among women …
men. Cervical cancer, caused by HPV, is the fourth most common cancer among women …
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
X Castellsagué, N Muñoz, P Pitisuttithum… - British journal of …, 2011 - nature.com
Background: Previous analyses from a randomised trial in women aged 24–45 years have
shown the quadrivalent human papillomavirus (qHPV) vaccine to be efficacious in the …
shown the quadrivalent human papillomavirus (qHPV) vaccine to be efficacious in the …
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post …
PS Naud, CM Roteli-Martins… - Human vaccines & …, 2014 - Taylor & Francis
HPV-023 (NCT00518336; ClinicalTrial. gov) is a long-term follow-up of an initial double-
blind, randomized (1: 1), placebo-controlled study (HPV-001, NCT00689741) evaluating the …
blind, randomized (1: 1), placebo-controlled study (HPV-001, NCT00689741) evaluating the …
Efficacy, safety, and immunogenicity of an Escherichia coli-produced human papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a …
FH Zhao, T Wu, YM Hu, LH Wei, MQ Li… - The Lancet Infectious …, 2022 - thelancet.com
Summary Background This Escherichia coli-produced bivalent HPV 16 and 18 vaccine was
well tolerated and effective against HPV 16 and 18 associated high-grade genital lesions …
well tolerated and effective against HPV 16 and 18 associated high-grade genital lesions …
Cervical cancer prevention in low-and middle-income countries: feasible, affordable, essential
VV Sahasrabuddhe, GP Parham… - Cancer prevention …, 2012 - AACR
The annual worldwide burden of the preventable disease cervical cancer is more than
530,000 new cases and 275,000 deaths, with the majority occurring in low-and middle …
530,000 new cases and 275,000 deaths, with the majority occurring in low-and middle …
Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women
J Luna, M Plata, M Gonzalez, A Correa, I Maldonado… - PLoS one, 2013 - journals.plos.org
Background Previous analyses from a randomized trial in women aged 24–45 have shown
the quadrivalent HPV vaccine to be efficacious in the prevention of infection, cervical …
the quadrivalent HPV vaccine to be efficacious in the prevention of infection, cervical …
HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future
L Mariani, A Venuti - Journal of translational medicine, 2010 - Springer
Although long-term protection is a key-point in evaluating HPV-vaccine over time, there is
currently inadequate information on the duration of HPV vaccine-induced immunity and on …
currently inadequate information on the duration of HPV vaccine-induced immunity and on …
Age-specific prevalence of human papilloma virus infection among Nigerian women
SN Akarolo-Anthony, AO Famooto, EO Dareng… - BMC public health, 2014 - Springer
Background Inconsistent trends in HPV prevalence by age have been described in Africa.
We examined the age prevalence pattern and distribution of 37 HPV-DNA types among …
We examined the age prevalence pattern and distribution of 37 HPV-DNA types among …
Ten‐year immune persistence and safety of the HPV‐16/18 AS 04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
TF Schwarz, A Galaj, M Spaczynski, J Wysocki… - Cancer …, 2017 - Wiley Online Library
Women remain at risk of human papillomavirus (HPV) infection for most of their lives. The
duration of protection against HPV‐16/18 from prophylactic vaccination remains unknown …
duration of protection against HPV‐16/18 from prophylactic vaccination remains unknown …